Onset of Clinical Effects and Plasma Concentration of Fluvoxamine in Japanese Patients

Katoh, Yasuhiro; Uchida, Shinya; Kawai, Masayoshi; Takei, Noriyoshi; Mori, Norio; Kawakami, Junichi; Kagawa, Yoshiyuki; Yamada, Shizuo; Namiki, Noriyuki; Hashimoto, Hisakuni

doi:10.1248/bpb.33.1999

Cited by 8 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early onset of action may also reduce the occurrence of treatment discontinuations, which may be due to lack of efficacy, one of the commonest factors seen in routine settings. Thus, decrease in HAMD-17 score as early as day 7 may explain why very few patients discontinued the treatment due to lack of efficacy [30]. These findings correlate with a double-blind study wherein fluvoxamine was reported to have a relatively faster onset of therapeutic action when compared with other SSRIs [19].…”

Section: Discussionsupporting

confidence: 61%

Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label, Uncontrolled and Non-Randomized Multicenter Observational Study

Smulevich¹,

Ilyina²

2015

OJPsych

View full text Add to dashboard Cite

Background: Fluvoxamine, a selective serotonin reuptake inhibitor is widely used in the treatment of depression, one of the most common disorders prevalent in Russia. However, studies demonstrating its efficacy and safety in routine settings in Russia are scarce. Methods: This prospective, uncontrolled, open-label study was conducted at 11 centers in Russia. Total 293 patients (aged ≥ 18 years), meeting DSM-IV criteria for depression and scoring ≥ 17 on 17-item Hamilton Rating Scale of Depression (HAMD-17) received fluvoxamine 50-300 mg for 6 weeks. Primary efficacy measures included change from baseline in the HAMD-17 and Clinical Global Impression (CGI) scores. Secondary efficacy measure was evaluation of sleep quality changes on HAMD-17 subscale. Safety was assessed by monitoring of adverse drug reactions (ADRs). Results: Mean age of patients was 42.7 years and the majority of them were women (72%). At the end of treatment (day 42), clinically significant reduction was observed in mean HAMD-17, CGI-severity of illness and HAMD-17 sleep sub-score from 23.1, 4.5 and 3.9 at baseline to day 42; change from baseline (∆) was: ∆-17.3 [95% CI: −18.0; −16.7]), ∆-2.1 and ∆-3.4 [95% CI: −3.53; −3.20]), respectively. At day 42, 20.8% patients reported as normal (not at all ill) on the CGI-severity scale and 85% patients reported as "much improved" or "very much improved" on the CGI-change in severity and quality of life scores. Nausea (12.6%) and somnolence (5.1%) were the most frequently reported ADRs. No deaths or serious ADRs were reported but eight patients discontinued treatment due to ADRs. Conclusion: Treatment with fluvoxamine under routine settings showed marked improvement in Russian patients with depression as measured by HAMD-17 and CGI ratings and was thus efficacious as well as safe and well-tolerated.

show abstract

Section: Discussionsupporting

confidence: 61%

Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label, Uncontrolled and Non-Randomized Multicenter Observational Study

Smulevich¹,

Ilyina²

2015

OJPsych

View full text Add to dashboard Cite

show abstract

“…Fluvoxamine is an SSRI that is widely used in the treatment of depression and other psychiatric disorders including anxiety disorders, and it has been suggested to have early effects when used as an antidepressant drug. 13 , 14 In addition, the results of a recent meta-analysis also suggest that treatment with fluvoxamine leads to symptomatic improvements in patients with MDD by the end of the first week of use. 15 …”

Section: Introductionmentioning

confidence: 99%

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder

Yoshimura

Katsuki

Atake

et al. 2017

NDT

View full text Add to dashboard Cite

ObjectivesThe etiology of depression remains unknown. There is, however, a growing body of evidence that cytokines are involved in the pathophysiology of depression. The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state.Subjects and methodsThirty patients who met the DSM-IV criteria for major depressive disorder (MDD) were enrolled in the study. Thirteen were male and 17 were female, and their ages ranged from 26 to 70 years (mean ± standard deviation 45.0±14.2). The patients were treated with fluvoxamine for 8 weeks. The dosages of fluvoxamine varied among the patients and, based on ethical considerations, were not fixed.ResultsThe fluvoxamine doses were positively related to plasma fluvoxamine levels (r =0.8798, P<0.001). A significant correlation was observed between the patients’ plasma IL-6 levels and their 17-item Hamilton Rating Scale for Depression (HAMD17) scores (r =0.4555, P=0.0010). A positive correlation was found between the delta plasma IL-6 (week 0–week 8) and the delta HAMD17 (week 0–week 8) (r =0.5226, P=0.002).ConclusionEffect of fluvoxamine on IL-6 is partially associated with its clinical efficacy for MDD.

show abstract

“…A wide variety of pharmaceuticals are available for treating depression, including tricyclic antidepressants, monoamine oxidase inhibitors, and selective serotonin reuptake inhibitors (SSRIs). Fluvoxamine is an SSRI that is widely used for treatment of depression and other psychiatric disorders and has been suggested to have early effects when used as an antidepressant drug [4,5]. In addition, the results of a meta-analysis have shown that significant improvements in Hamilton Rating Scale for Depression (HAMD) scores achieved in the first few weeks were maintained after 6 weeks of treatment [6].…”

Section: Introductionmentioning

confidence: 99%

Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients

et al. 2014

View full text Add to dashboard Cite

BackgroundWe investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.MethodsFifty-one patients with MDD (M/F, 19:32; age, 38 ± 19 years) and 51 healthy controls (M/F, 22:29; age, 34 ± 17 years) were studied using DSM-IV-TR: physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders. Serum levels of proBDNF and MDNF were measured by sandwich enzyme-linked immunosorbent assay (ELISA).ResultsSerum mature BDNF levels in the MDD patients were significantly lower than those in the healthy controls (t = 3.046, p = 0.0018). On the other hand, no difference was found in serum proBDNF between the MDD patients and the healthy controls (t = −0.979, p = 0.833). A trend of negative correlation was found between baseline serum BDNF and baseline scores of the 17 items of the Hamilton Rating Scale for Depression (HAMD17) (r = −0.183, p = 0.071). No correlation was however found between HAMD17 scores and proBDNF at baseline (r = 0.092, p = 0.421). Furthermore, no correlation was observed between baseline HAMD17 scores and baseline proBDNF/BDNF (r = −0.130, p = 0.190). No changes were observed in serum levels of proBDNF and BDNF during the treatment periods.ConclusionsThese results suggest that there is no association between serum proBDNF/BDNF and fluvoxamine response in MDD patients at least within 4 weeks of the treatment.

show abstract

Onset of Clinical Effects and Plasma Concentration of Fluvoxamine in Japanese Patients

Cited by 8 publications

References 20 publications

Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label, Uncontrolled and Non-Randomized Multicenter Observational Study

Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label, Uncontrolled and Non-Randomized Multicenter Observational Study

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder

Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients

Contact Info

Product

Resources

About